Biotron Ltd

BIT.AU

$0.05

Closing

▲2.60%

1D

▼-18.56%

YTD

Market cap

$44.21M

52 week high

$0.08

52 week low

$0.02

Volume

1,154,620

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$44.21M

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

Operating Margin

-252.08%

Beta

0.20

Revenue Growth (Annual)

-14.79%

52 week high

$0.08

52 week low

$0.02

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Biotron Limited is a biotechnology company. The Company is engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company is engaged in developing and commercializing a small molecule approach that has the potential to treat a number of serious viral diseases. Its primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. BIT225 is its lead antiviral clinical-stage, investigational, small molecule antiviral drug. BIT225 is in Phase II development for the treatment of human immunodeficiency virus-1 (HIV-1) and Hepatitis C virus infections. It also has commenced a program to develop an antiviral drug to treat SARS-CoV-2 infection. Its BIT225 drug has shown clinical efficacy against SARS-CoV-2 in early-stage research studies. It also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as Dengue, Zika and Influenza virus.